GSK ‘welcomes’ plaintiff’s voluntary dismissal of Kasza Zantac case

GSK issued the following statement: “GSK plc welcomes the plaintiff’s voluntary dismissal of the next Zantac case, or “Kasza,” which was scheduled to start trial in Illinois state court on June 10, 2024. GSK did not settle Ms. Kasza’s claim and has not paid anything in exchange for the voluntary dismissal. Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer. GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.”